Ex-GSK Melanoma Therapy Secures EU Approval For Novartis

Novartis AG has been granted European approval for two products it picked up via a $20bn mega deal transaction with GlaxoSmithKline plc, a deal which closed in March this year.

More from Anticancer

More from Therapy Areas